Independent Bank Corp. Third Quarter Earnings Call - INDEPENDENT BANK CORP

Explicit Guidance:

• Q4 2026 Revenue & Margins: Net interest income (NII) expected to increase modestly versus Q3; reported net interest margin (NIM) anticipated to land slightly above 3.9% (assuming no further Fed action), which includes an estimated 10 basis point benefit from loan accretion. Fee income anticipated to grow in the low single-digit percentage range. Operating expenses expected to be up slightly over Q3, excluding system conversion costs.
• Q4 2026 Expenses: Approximately $1 million to $1.5 million of one-time expenses anticipated for core conversion (majority incurred in Q4).
• Q4 2026 Loan Growth: Construction loans projected to increase at a low single-digit annualized percentage; Commercial & Industrial (C&I) loans anticipated to grow at a mid-single-digit annualized rate. Home equity expected to maintain high single-digit annualized growth; mortgage balances projected to remain flat to low single-digit growth.
• Q4 2026 Deposit Growth: Period-end deposits likely flat to low single-digit annualized growth rate (seasonality considered).
• 2027 Guidance: Full-year 2027 guidance (revenue, earnings, margins, expenses) to be provided with Q4 2026 results. Tax rate expected to remain consistent at 23.3% for Q4; no material changes anticipated for the period.
• Capital Returns: Reaffirmed commitment to return 100% of profits via dividends and buybacks; capacity exists to be slightly more aggressive, though no specific buyback volume guidance for Q4 or 2027 provided.

Business-Segment Outlook:

• Loan Pipeline: Approved commercial loan pipeline stands at $574 million (up from $510 million in Q2), driven by strong origination and a strategic pivot by relationship managers. Pipeline conversion ratio historically yields ~$400M funding from a ~$500M commitment.
• Asset Classes:
  • CNI: Pipeline healthy; anticipated to continue mid-single-digit growth through Q4 2026 and into 2027.
  • Commercial Real Estate (CRE): CREE concentration at 27.8%. Expect low single-digit growth in CRE/construction balances due to sustained construction draw activity and reduced payoffs (payoffs down 27% QoQ).
  • Consumer: Home equity demand remains strong (high single-digit growth); residential mortgage activity challenged by higher rates (portfolio mix shifting to ~80% purchase, 20% refinance).
• Credit Quality: Net charge-offs expected to remain low (~2 bps annualized). Approximately $17 million in specific reserves (largely office and life sciences) anticipated to be charged off over the next couple of quarters, but no significant additional provision required.
• Core Systems Conversion: Core systems upgrade timeline revised from October to February 2027. Expected to drive enhanced operational efficiencies and product capabilities upon completion.
• Headquarters Consolidation: Moving ~400 employees to a single location (Rockland, Mass.) in November 2026 to foster collaboration and operational efficiency.

Market and Competitive Outlook:

• Deposit Competition: Acknowledged as "very high." Strategy remains focused on being competitive for the right deals while avoiding balance sheet growth at thin risk-adjusted spreads.
• Loan Demand: C&I growth driven by new client acquisition (non-seasonal). CRE construction activity robust despite higher rates; payoffs expected to return to historical levels rather than the elevated levels seen in Q2.
• Mortgage Market: Saleable mortgage banking and loan-level swap activity softened due to the higher rate environment.
• Branch Expansion: Active dialogue with potential hires in New Hampshire (Manchester, Portsmouth) and Rhode Island (Providence) to capture new markets where the bank currently lacks a physical footprint.
• Capital Management: CET1 ratio at 12.7%; tangible capital ratio at 9.4%. Flexibility to maintain aggressive buyback activity despite OCI pressure from unrealized losses.

Macro / Industry Outlook:

• Interest Rates: Management anticipates the Federal Reserve may continue to move rates higher.
  • NIM Impact: Assumes "no further Fed action" yields >3.9% NIM in Q4. A 4% NIM is viewed as achievable by end of 2027 driven by back-book repricing (over $500M of securities cash flows over next 4–5 quarters) and loan yield improvements.
  • Rate Sensitivity: If Fed hikes occur in Q4, anticipated margin impact is a few basis points reduction. For 2027, a 1-2 hike scenario is expected to be largely offset by loan yield repricing on the non-CD book (25% exposure), though CD cost increases could create a slight drag.
• Economic Headwinds: Management cites "higher interest rates, inflationary concerns, the Iran War, [and] tariffs" as challenging economic landscape factors, though no credit degradation has been observed thus far.
• Securities Portfolio: Purchasing weighted average yield at ~5% (up to ~6% in Sept); focus on low-coupon, deep-discounted MBS for downside protection.

Strategic Initiatives:

• Technology: Advancement of AI applications (beta testing internal use cases first); core systems conversion to complete in Feb 2027.
• Capital Deployment: Continued aggressive stock buybacks ($57.4M in Q3) and dividend payouts targeting 100% of profits.
• Debt Management: Paid down $100M FHLB borrowing; converted remaining $25M holding company line into a 3-year term loan; executed new $125M holding company term loan.
• Organic Growth: Strategy focused on deepening profitable customer relationships rather than rapid balance sheet expansion.

Risks and Headwinds to Outlook:

• Credit Risks: Office and life sciences portfolios face specific reserve charges ($17M expected charge-offs over next quarters); specific loan workout status (e.g., $22.4M office loan conversion to multifamily, SNCC portfolio).
• Operational Risks: Core conversion delays (pushed to Feb) to avoid customer disruption; potential for accelerated rent expenses on vacated facilities in 2027.
• Interest Rate Risks: Higher rates may pressure saleable mortgage volume and pause business spending in CRE; potential for CD cost increases to outpace loan yield repricing if the curve steepens further.
• Competition: High deposit rate competition could increase cost of funds.
• Regulatory/Geopolitical: Explicit mention of Iran War and tariffs as external variables; potential for tax or assessment changes.

Management Tone on the Future:

• Confidence: "Proud" of Q3 results; confident in the path to a 4% NIM by end of 2027. Tone is "laser focused" on operational execution.
• Prudence: Shift in core conversion timeline reflects a "measured approach" prioritizing "getting it done right" over speed.
• Discipline: Emphasis on "disciplined underwriting," "prudent growth," and "tight expense management" despite competitive pressures.
• Capital Discipline: Willing to "hold the line" on operating expenses while selectively investing in AI and technology.

Miscellaneous:

• One-Time Adjustments: Q3 included a $1M benefit from life insurance split-dollar valuation and a $400K FDIC assessment retroactive adjustment; Q3 also included $900K in director equity grant expenses (minimal in Q3).
• Asset Yields: New commercial loan pricing averaging ~6.5% (up from ~5% older fixed loans); securities yields expected to rise to ~6%.
• Q&A Clarifications: Clarified that $17M in life science non-performers is the sole non-performer in that book; office non-performers total ~$62M across three loans (including the new $22.4M loan).